Recurrent Pancreatic Carcinoma Active Not Recruiting Phase 1 Trials for Dasatinib (DB01254)

Also known as: Pancreatic carcinoma recurrent / Pancreas carcinoma recurrent / Pancreatic cancer recurrent

IndicationStatusPhase
DBCOND0043478 (Recurrent Pancreatic Carcinoma)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01660971Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by SurgeryTreatment